Clene Inc. (CLNNW) Stock Analysis

Clene Inc. (CLNNW) Healthcare & Pipeline Overview

Clene Inc. is a clinical-stage pharmaceutical company leveraging proprietary clean-surfaced nanotechnology (CSN) to develop novel therapeutics. The company's pipeline targets neurodegenerative diseases like ALS, MS, and Parkinson's with its lead candidate CNM-Au8, alongside other nanotechnology-based solutions for infectious diseases and wound healing.

What Is the Investment Thesis for CLNNW?

Clene Inc. presents a research-driven profile centered on its proprietary clean-surfaced nanotechnology (CSN) platform, which underpins its diverse pipeline of therapeutic candidates. The primary value driver is the progress and potential regulatory approval of CNM-Au8, particularly its ongoing Phase 2/3 registrational clinical trial for ALS. Successful outcomes in this pivotal trial could significantly de-risk the asset and open a substantial market opportunity in a disease with high unmet need. Further growth catalysts include positive data readouts from ongoing Phase 2 trials for CNM-Au8 in Parkinson's Disease and the potential advancement of its infectious disease candidates, CNM-AgZn17 and CNM-ZnAg, into later-stage development. The company's strategic focus on diseases with limited treatment options, coupled with its unique nanotechnology approach, positions it for potential long-term value creation. However, as a clinical-stage company, Clene Inc. faces inherent risks associated with clinical trial success, regulatory approvals, and the need for substantial capital to fund its research and development initiatives, reflected in its current negative profit and gross margins.

Based on FMP financials and quantitative analysis

CLNNW Key Highlights

Clene Inc. operates with a negative profit margin of -25009.7%, indicative of its clinical-stage status and significant R&D investments.

• The company's gross margin stands at -182.1%, reflecting that current operational expenses significantly exceed any revenue generated from its dietary supplement sales.
• Clene Inc. maintains a market capitalization of $2.16M, characteristic of a development-stage biotechnology firm with no commercialized pharmaceutical products.
• The stock exhibits a Beta of 0.79, suggesting lower volatility compared to the broader market, which is uncommon for a clinical-stage biotech company.
• Clene Inc. does not currently pay a dividend, aligning with typical practices for companies prioritizing reinvestment into research and development.

Who Are CLNNW's Competitors?

CLNNW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CLNNW's Key Strengths?

Proprietary clean-surfaced nanotechnology (CSN) platform with broad therapeutic potential.

• Lead drug candidate CNM-Au8 is in a Phase 2/3 registrational trial for ALS, a high-unmet-need indication.
• Diversified pipeline addressing neurodegenerative diseases, infectious diseases, and wound healing.
• Completed multiple Phase 2 trials for CNM-Au8 across various neurological conditions.
• Existing market presence with dietary supplements KHC46 and rMetx.

What Are CLNNW's Weaknesses?

Negative profit and gross margins, indicating significant cash burn typical of a clinical-stage company.

• Reliance on successful clinical trial outcomes for future commercial viability.
• Limited revenue streams currently, primarily from dietary supplements.
• High capital requirements for ongoing and future research and development activities.
• Small employee base (75 employees) for a company with multiple drug candidates in development.

What Could Drive CLNNW Stock Higher?

CLNNW catalyst: Public release of top-line data or interim results from the ongoing Phase 2/3 registrational clinical trial for CNM-Au8 in patients with Amyotrophic Lateral Sclerosis (ALS).

• Further progress or data readouts from the second Phase 2 clinical trial for CNM-Au8 in the treatment of patients with Parkinson's Disease.
• Advancement of CNM-AgZn17 into later-stage clinical development or initiation of new trials for infectious diseases and wound healing applications.
• Continued enrollment and progression of existing clinical trials for CNM-Au8 across its various neurological indications.
• Potential regulatory submissions or designations (e.g., Fast Track, Orphan Drug) based on promising clinical data for any of its lead candidates.

What Are the Key Risks for CLNNW?

Financial-distress signal — its Altman Z-Score of -22.83 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or unfavorable safety/efficacy results for lead drug candidates, particularly CNM-Au8, which could lead to development halts and significant financial impact.
• Significant regulatory hurdles, delays in obtaining necessary approvals, or adverse decisions from health authorities for its nanotechnology therapeutics.
• High operational costs associated with extensive clinical development and research, potentially necessitating substantial future capital raises and diluting existing shareholder value.
• Intense competition within the biotechnology sector from companies developing treatments for neurodegenerative and infectious diseases, potentially limiting market share.
• Challenges in manufacturing complex nanotechnology-based therapeutics at scale or maintaining consistent product quality for commercialization.

What Are the Growth Opportunities for CLNNW?

• Growth opportunity 1: **Advancement of CNM-Au8 in ALS Treatment.** Clene Inc.'s lead drug, CNM-Au8, is currently in a Phase 2/3 registrational clinical trial for amyotrophic lateral sclerosis (ALS). The global ALS treatment market is projected to reach significant valuations, driven by increasing incidence and the need for disease-modifying therapies. A successful outcome in this pivotal trial, leading to regulatory approval, would unlock a substantial market opportunity for Clene Inc. and establish CNM-Au8 as a potential new standard of care. The timeline for this opportunity is tied directly to the completion and readout of the ongoing registrational trial and subsequent regulatory submissions, which could span the next few years.
• Growth opportunity 2: **Expansion into Parkinson's Disease Therapeutics.** CNM-Au8 is also undergoing a second Phase 2 clinical trial for the treatment of patients with Parkinson's Disease, a chronic and progressive neurodegenerative disorder affecting millions globally. The Parkinson's Disease therapeutics market is substantial and growing, driven by an aging population. Positive results from this Phase 2 trial could pave the way for larger, later-stage studies, positioning CNM-Au8 to address motor and non-motor symptoms. This represents a significant market expansion opportunity for Clene Inc. beyond ALS, with a timeline dependent on clinical trial progression and regulatory pathways.
• Growth opportunity 3: **Targeting Multiple Sclerosis with Remyelination Potential.** Clene Inc. has completed a Phase 2 clinical trial for CNM-Au8 for the treatment of visual pathway deficits in chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis (MS). The global MS market is a multi-billion dollar segment, with a continuous demand for therapies that can not only manage symptoms but also promote neurological repair. Demonstrating remyelination capabilities could differentiate CNM-Au8 significantly, offering a novel mechanism of action in a crowded but innovation-hungry market. Further development in this area could provide another major revenue stream.
• Growth opportunity 4: **Development of CNM-AgZn17 for Infectious Diseases and Wound Healing.** The company is developing CNM-AgZn17, a gel polymer suspension of silver and zinc ions, for the treatment of infectious diseases and to support wound healing. The global market for wound care management and anti-infectives is vast and continually expanding due to rising chronic diseases, surgical procedures, and antibiotic resistance. Advancing CNM-AgZn17 through clinical development and potential commercialization could tap into these large and diverse markets, offering a nanotechnology-based solution for critical healthcare needs. This represents a diversification beyond neurodegeneration.
• Growth opportunity 5: **Leveraging CNM-ZnAg as a Broad-Spectrum Antiviral/Antibacterial.** Clene Inc.'s CNM-ZnAg is being developed as a broad-spectrum antiviral and antibacterial agent, with specific mention of its potential to treat infectious diseases like COVID-19 and provide immune support. The market for antiviral and antibacterial agents, particularly those with broad-spectrum activity, remains robust, especially in the wake of global health crises. Successful development and regulatory approval of CNM-ZnAg could position Clene Inc. to address ongoing and future infectious disease challenges, offering a novel therapeutic option and contributing to public health preparedness. The market size for such agents is immense and responsive to emerging threats.

What Threats Does CLNNW Face?

• Failure of lead drug candidates in clinical trials, particularly CNM-Au8, leading to significant value erosion.
• Intense competition from established pharmaceutical companies and other biotechnology firms.
• Stringent and unpredictable regulatory approval processes for novel therapeutics.
• Need for substantial future funding, potentially leading to dilution for existing shareholders.
• Market acceptance challenges for nanotechnology-based therapeutics or dietary supplements.

What Are CLNNW's Competitive Advantages?

• Proprietary clean-surfaced nanotechnology (CSN) platform, offering a unique drug delivery and mechanism of action.
• Extensive clinical trial data and ongoing registrational trials for lead candidate CNM-Au8 in high-unmet-need areas like ALS.
• Diversified pipeline addressing both neurodegenerative diseases and infectious diseases, leveraging a common technological base.
• Intellectual property surrounding its specific nanoparticle formulations and their therapeutic applications.
• Early-mover advantage in applying specific metallic nanoparticles for neurological and anti-infective indications.

What Does CLNNW Do?

Clene Inc., headquartered in Salt Lake City, Utah, operates as a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's foundational premise revolves around its unique CSN platform, which aims to deliver active pharmaceutical ingredients with enhanced precision and efficacy. Clene Inc.'s lead drug candidate, CNM-Au8, is a prime example of this technology, currently undergoing extensive clinical investigation across multiple neurodegenerative conditions. This includes an ongoing Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS), building upon a completed Phase 2 proof-of-concept trial for early symptomatic ALS. Furthermore, CNM-Au8 has been evaluated in two completed open-label, investigator-blinded Phase 2 clinical trials focusing on the brain's energy metabolites, a completed Phase 2 trial for treating visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis, and a second Phase 2 clinical trial for Parkinson's Disease patients. Beyond neurological disorders, Clene Inc. is also developing CNM-AgZn17, a gel polymer suspension of silver and zinc ions, for the treatment of infectious diseases and to support wound healing. Another product, CNM-ZnAg, is positioned as a broad-spectrum antiviral and antibacterial agent, with potential applications in treating infectious diseases like COVID-19 and providing immune support for symptom resolution. Complementing its pharmaceutical pipeline, the company markets and distributes dietary supplements, including rMetx, an aqueous zinc-silver ion supplement, and KHC46, an aqueous gold dietary supplement comprising very low-concentration gold nanoparticles, demonstrating a diversified approach within the health and wellness sector. With a team of 75 employees, Clene Inc. is committed to advancing its nanotechnology platform to address significant unmet medical needs.

What Products and Services Does CLNNW Offer?

• Develops novel clean-surfaced nanotechnology (CSN) therapeutics for various diseases.
• Conducts clinical trials for its lead drug candidate, CNM-Au8, targeting neurodegenerative conditions.
• Focuses on Amyotrophic Lateral Sclerosis (ALS) with CNM-Au8 in a Phase 2/3 registrational trial.
• Investigates CNM-Au8 for Parkinson's Disease and Multiple Sclerosis (MS) in Phase 2 trials.
• Develops CNM-AgZn17 for infectious diseases and wound healing applications.
• Researches CNM-ZnAg as a broad-spectrum antiviral and antibacterial agent, including for COVID-19.
• Markets and distributes dietary supplements, rMetx and KHC46, containing zinc-silver ions and gold nanoparticles, respectively.
• Utilizes its headquarters in Salt Lake City, Utah, for its research and development operations.

How Does CLNNW Make Money?

• Primarily a research and development (R&D) focused company, investing heavily in clinical trials for drug candidates.
• Aims to generate future revenue through the commercialization and sales of its proprietary CSN therapeutics upon regulatory approval.
• Currently generates some revenue through the marketing and distribution of dietary supplements (rMetx and KHC46).
• Relies on capital raises and strategic partnerships to fund its extensive clinical development pipeline.
• Seeks to establish intellectual property rights for its nanotechnology platform and drug candidates to secure market exclusivity.

What Industry Does CLNNW Operate In?

Clene Inc. operates within the highly specialized and competitive Biotechnology industry, a sub-sector of Healthcare characterized by extensive research and development, lengthy clinical trials, and stringent regulatory processes. The company's focus on neurodegenerative diseases like ALS, Multiple Sclerosis, and Parkinson's places it in therapeutic areas with significant unmet medical needs and substantial market potential. The broader biotechnology market is driven by scientific innovation, advancements in understanding disease mechanisms, and the increasing demand for novel treatments. Clene Inc.'s clean-surfaced nanotechnology (CSN) platform represents a distinct approach within this landscape, aiming to differentiate its drug candidates from conventional therapies. Competition is intense, with numerous pharmaceutical giants and smaller biotechs vying for market share in these lucrative therapeutic areas. Success in this industry hinges on robust clinical data, intellectual property protection, and efficient navigation of regulatory pathways, positioning Clene Inc. as a high-risk, high-reward player in a dynamic and evolving market.

Who Are CLNNW's Key Customers?

• Patients suffering from neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Parkinson's Disease.
• Healthcare providers and institutions seeking novel therapeutic options for neurological disorders.
• Individuals requiring treatment for infectious diseases or support for wound healing.
• Consumers interested in dietary supplements for immune support and general wellness (rMetx and KHC46).
• Pharmaceutical and biotechnology partners for potential licensing or co-development agreements.

Company Profile

Clene Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Salt Lake City, US. The company is led by CEO Robert Etherington. CLNNW has traded publicly since 2018.

Clene Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -22.83 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Clene Inc. stands at 215.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 3.07 indicates the company holds enough short-term assets to cover its near-term obligations.

CLNNW Valuation & Market Position

With a $2.16M market cap, Clene Inc. sits in the micro-cap segment of the market.

Wall Street analysts project Clene Inc. revenue of about $243K for fiscal 2026, with EPS near $-2.06. The estimate reflects 7 contributing analysts.

CLNNW Financials

CLNNW Latest News

No recent news available for CLNNW.

CLNNW Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources